2022 / 02

DOI: 10.24075/brsmu.2022.023

ORIGINAL RESEARCH

Development of a recombinant oncolytic poliovirus type 3 strain with altered cell tropism

Hamad A1,2,3, Soboleva AV1, Vorobyev PO1, Mahmoud M1,2, Vasilenko KV4, Chumakov PM1, Lipatova AV1
About authors

1 Engelhardt Institute of Molecular Biology, Moscow, Russia

2 Moscow Institute of Physics and Technology (MIPT), Moscow, Russia

3 Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Moscow, Russia

4 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Anastasia V. Lipatova
Vavilova, 32/1, Moscow, 119991, Russia; moc.liamg@vnaavotapil

About paper

Funding: the project was supported by the Russian Science Foundation (agreement number 20-75-10157 of 14 August 2020 “Research on the possibilities of obtaining recombinant strains of oncolytic viruses with tumor-specific replication and immunomodulatory protein expression”).

Author contribution: Chumakov PM, Lipatova AV — study concept and planning, data analysis; Hamad A, Vorobyev PO, Soboleva AV, Mahmoud M, Vasilenko KV, and Lipatova AV — laboratory experimental work; Hamad A, Soboleva AV, and Lipatova AV — preparation of figures and data interpretation.

Compliance with ethical standards: the study was conducted per the requirements of the World Medical Association Declaration of Helsinki 2000 and its subsequent revisions; in compliance with the principles of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes.

Received: 2022-04-18 Accepted: 2022-04-28 Published online: 2022-04-30
|
  1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, FigarellaBranger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23: 1231–51.
  2. Carpenter AB. Recombinant oncolytic poliovirus for glioblastoma: A current review of PVS (RIPO). Georgetown Medical Review. 2019; 3: 7789.
  3. Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, et al. Oncolytic polio virotherapy of cancer. Cancer. 2014; 120: 3277–86.
  4. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018; 174: 1031–2.
  5. Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018; 18: 419–32.
  6. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proceedings of the National Academy of Sciences. 1996; 93: 2370–5.
  7. Desjardins A, Gromeier M, Herndon JE, 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; 379: 150–61.
  8. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004; 4: 73.
  9. Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer research. 2015; 35: 2287–97.
  10. Merrill MK,Gromeier M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. Journal of Virology. 2006; 80: 6936–42.
  11. López-Ulloa B, Fuentes Y, Pizarro-Ortega MS, López-Lastra M. RNA-Binding Proteins as Regulators of Internal Initiation of Viral mRNA Translation. Viruses. 2022; 14.
  12. Merrill MK, Dobrikova EY, Gromeier M. Cell-type-specific repression of internal ribosome entry site activity by doublestranded RNA-binding protein 76. J Virol. 2006; 80: 3147–56.
  13. Kauder SE,Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004; 113: 1743–53.
  14. Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA, et al. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer. 2021; 9.
  15. Aslanidis C, de Jong PJ, Schmitz G. Minimal length requirement of the single-stranded tails for ligation-independent cloning (LIC) of PCR products. PCR Methods Appl. 1994; 4: 172–7.
  16. Yun T, Park A, Hill TE, Pernet O, Beaty SM, Juelich TL, et al. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol. 2015; 89: 1242–53.
  17. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of SARS-CoV-2 neutralizing antibody by wildtype plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nature Protocols. 2021; 16: 3114–40.
  18. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American journal of epidemiology. 1938; 27: 493–7.
  19. Lipatova AV, Soboleva AV, Gorshkov VA, Bubis JA, Solovyeva EM, Krasnov GS, et al. Multi-Omics Analysis of Glioblastoma Cells’ Sensitivity to Oncolytic Viruses. Cancers (Basel). 2021; 13: 1–19.
  20. Sabin A. Oral poliovirus vaccine: Histry of its development and prospects for eradication of poliomyelitis. JAMA. 1965; 194 130–4.
  21. Boulger L,Magrath D. Differing neurovirulence of three Sabin attenuated type 3 vaccine seed pools and their progeny. Journal of Biological Standardization. 1973; 1: 139–47.
  22. Bianchi FP, Larocca AMV, Bozzi A, Spinelli G, Germinario CA, Tafuri S, et al. Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study. Vaccine. 2021; 39: 2989–94.
  23. Golikov MV, Karpenko IL, Lipatova AV, Ivanova ON, Fedyakina IT, Larichev VF, et al. Cultivation of Cells in a Physiological Plasmax Medium Increases Mitochondrial Respiratory Capacity and Reduces Replication Levels of RNA Viruses. Antioxidants. 2021; 11: 97.